Novelix Pharmaceuticals Ltd

₹ 66.5 -0.31%

10 Jul - close price

About

Incorporated in 1994, Novelix Pharmaceuticals Ltd trades in Pharmaceuticals and related products , shares, and securities^[1]

Key Points

Business Overview:^[1]^[2]^[3]
NPL is a recent entrant in the life sciences research and pharmaceutical intermediates business. In FY24, the company altered its objectives to expand into the pharmaceutical bulk drug segment and healthcare research, analytics, and technology. Currently, it is engaged in pharmaceutical research and the production and trading of bulk drugs (Active Pharmaceutical Ingredients) as well as key starting materials and intermediates.

Website BSE

Market Cap ₹ 159 Cr.
Current Price ₹ 66.5
High / Low ₹ 92.0 / 38.0
Stock P/E 62.1
Book Value ₹ 22.0
Dividend Yield 0.00 %
ROCE 9.98 %
ROE 8.00 %
Face Value ₹ 10.0

Add ratio to table

Edit ratios

Pros

Company is almost debt free.
Promoter holding has increased by 4.06% over last quarter.
Company's median sales growth is 42.1% of last 10 years
Company's working capital requirements have reduced from 222 days to 122 days

Cons

Stock is trading at 3.02 times its book value
Though the company is reporting repeated profits, it is not paying out dividend
Company has a low return on equity of 5.12% over last 3 years.
Company has high debtors of 163 days.
Promoter holding has decreased over last 3 years: -16.4%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Healthcare Services Healthcare Research, Analytics & Technology

Edit Columns

Loading peers table ...

Detailed Comparison with:

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
	0.87	1.95	0.93	0.50	0.84	0.60	3.96	5.30	20.86	22.35	36.36	48.40	25.19
	1.07	2.14	1.04	0.61	0.69	1.04	3.74	5.17	20.63	22.17	35.66	47.09	23.91
Operating Profit	-0.20	-0.19	-0.11	-0.11	0.15	-0.44	0.22	0.13	0.23	0.18	0.70	1.31	1.28
OPM %	-22.99%	-9.74%	-11.83%	-22.00%	17.86%	-73.33%	5.56%	2.45%	1.10%	0.81%	1.93%	2.71%	5.08%
	0.23	0.05	0.05	0.09	0.13	0.10	-0.08	0.00	0.00	0.00	0.03	0.00	0.00
Interest	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Depreciation	0.01	0.01	0.01	0.01	0.01	0.00	0.00	0.00	0.02	0.01	0.01	0.03	0.05
Profit before tax	0.02	-0.15	-0.07	-0.03	0.27	-0.34	0.14	0.13	0.21	0.17	0.72	1.28	1.23
Tax %	0.00%	6.67%	0.00%	0.00%	0.00%	2.94%	0.00%	-15.38%	14.29%	41.18%	26.39%	21.88%	26.02%
	0.01	-0.17	-0.07	-0.03	0.28	-0.35	0.13	0.15	0.18	0.11	0.53	1.00	0.91
EPS in Rs	0.01	-0.21	-0.09	-0.04	0.35	-0.35	0.13	0.15	0.18	0.09	0.37	0.58	0.43
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	1	1	4	3	4	2	1	1	2	4	31	132
	1	1	3	3	3	1	4	3	2	4	31	129
Operating Profit	0	0	0	0	0	0	-3	-2	0	-0	0	3
OPM %	33%	43%	5%	15%	6%	12%	-244%	-151%	0%	-6%	0%	3%
	0	0	0	-0	0	0	0	0	0	0	0	0
Interest	0	0	0	0	0	0	0	0	0	0	0	0
Depreciation	0	0	0	0	0	0	0	0	0	0	0	0
Profit before tax	0	0	0	0	0	0	-3	-2	-0	0	0	3
Tax %	88%	31%	24%	34%	-32%	20%	0%	-1%	0%	50%	33%	25%
	0	0	0	0	0	0	-3	-2	-0	0	0	3
EPS in Rs	0.02	0.12	0.19	0.22	0.31	0.11	-4.04	-1.93	-0.07	0.01	0.08	1.21
Dividend Payout %	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Compounded Sales Growth
10 Years:	63%
5 Years:	152%
3 Years:	310%
TTM:	331%

Compounded Profit Growth
10 Years:	40%
5 Years:	23%
3 Years:	255%
TTM:	3100%

Stock Price CAGR
10 Years:	27%
5 Years:	55%
3 Years:	95%
1 Year:	33%

Return on Equity
10 Years:	-1%
5 Years:	2%
3 Years:	5%
Last Year:	8%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	8	8	8	8	8	8	8	8	8	8	10	21
Reserves	3	3	3	4	4	4	1	-1	-1	-1	8	25
	0	0	0	0	0	0	0	0	0	0	0	4
	0	0	0	0	0	0	0	0	0	0	10	42
Total Liabilities	12	12	12	12	12	12	9	7	7	7	27	92
	1	1	1	1	0	0	0	2	0	0	0	3
CWIP	0	0	0	0	0	0	0	0	0	0	0	0
Investments	1	3	2	3	3	4	4	1	3	3	0	0
	9	8	9	9	9	8	5	5	4	4	27	89
Total Assets	12	12	12	12	12	12	9	7	7	7	27	92

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	-0	2	-1	1	-0	1	1	1	-2	-0	-14	-22
	-0	-2	1	-1	0	-0	0	0	0	0	3	-2
	-0	0	0	0	0	0	0	0	0	0	11	26
Net Cash Flow	-1	0	-0	-0	0	1	1	1	-2	-0	1	2
Free Cash Flow	-1	2	-1	1	-0	1	0	-1	-2	-0	-14	-26
CFO/OP	-90%	472%	-535%	225%	-220%	672%	-18%	-34%		136%	-9,771%	-643%

Ratios

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	30	4	40	130	216	19	25	32	36	1	216	163
Inventory Days	0		28	19	13	39	89	239	222	113	10	42
Days Payable			0	54	13	5	4	0	14	0	115	116
Cash Conversion Cycle	30	4	68	95	216	54	111	271	244	114	111	88
Working Capital Days	2,225	2,584	863	932	858	1,711	819	647	743	346	197	122
ROCE %	1%	1%	1%	3%	1%	1%	-31%	-19%	-1%	0%	1%	10%

Insights

In beta

Mar 2016

Mar 2017

Mar 2018

Mar 2019

Mar 2020

Mar 2021

Mar 2022

Mar 2023

Mar 2024

Mar 2025

Closing stock of goods (pharma inventory)
INR '000

x,xxx.xx	x,xxx.xx	x,xxx.xx	x,xxx.xx	x,xxx.xx	x,xxx.xx	x,xxx.xx	x,xxx.xx	x,xxx.xx	x,xxx.xx
x.xx	x.xx	xx.xx	xx.xx	xx.xx	x.xx	x.xx	x.xx	x.xx	x.xx
xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	x.xx	x.xx	xx.xx	x.xx	xx.xx
x.xx	xx.xx	xx.xx	x.xx	x.xx	xx.xx	xx.xx	xx.xx	xx.xx	x.xx
		x,xxx.xx	x,xxx.xx	xxx.xx	x,xxx.xx	x,xxx.xx	x,xxx.xx	x,xxx.xx	x.xx
				x	x	x	x	x	x

Please log in to see hidden values.

Foods Business revenue share
%

Pharma Business revenue share
%

Trading in Shares revenue share
%

Closing stock of securities (shares inventory)
INR '000

Number of permanent employees on rolls
count

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	May 2026
	66.92%	66.92%	66.92%	66.54%	66.56%	66.56%	66.56%	52.75%	53.33%	51.97%	49.43%	50.57%
	33.08%	33.08%	33.08%	33.46%	33.44%	33.45%	33.44%	47.25%	46.66%	48.01%	50.57%	49.43%
No. of Shareholders	2,389	2,621	2,635	2,569	2,533	2,502	2,484	2,408	2,697	2,994	2,975	3,004

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	May 2026
	64.19%	64.19%	64.19%	64.19%	66.92%	66.92%	66.92%	66.92%	66.56%	49.43%	50.57%
	35.81%	35.81%	35.81%	35.81%	33.08%	33.08%	33.08%	33.08%	33.44%	50.57%	49.43%
No. of Shareholders	2,739	2,727	2,180	2,171	2,213	2,431	2,414	2,635	2,484	2,975	3,004

Documents

Announcements

All

Novelix Pharmaceuticals Ltd

Novelix Pharmaceuticals Ltd

Peer comparison

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flows

Ratios

Insights

Shareholding Pattern

Documents

Announcements

Annual reports